Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8156634 | 0.88 | S1PR1 (0.33) | CYP19A1S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL8148673 | 0.87 | S1PR1 (0.33) | CYP19A1S1PR1S1PR3 | |
| SCHEMBL3498549 | 0.83 | DAO (0.32) | CYP19A1ABCB1CNR1 | |
| SCHEMBL6437501 | 0.81 | CYP19A1 (0.41) | CYP19A1 | |
| SCHEMBL8149818 | 0.80 | EGLN1 (0.35) | CYP19A1 | |
| SCHEMBL8149036 | 0.78 | EGLN1 (0.33) | CYP19A1S1PR1S1PR3CNR1 | |
| SCHEMBL8157295 | 0.77 | EGLN1 (0.33) | CYP19A1 | |
| SCHEMBL8142506 | 0.77 | CYP19A1 (0.38) | CYP19A1 | |
| SCHEMBL8151901 | 0.75 | CYP19A1 (0.34) | CYP19A1 | |
| SCHEMBL3499500 | 0.73 | CYP19A1 (0.33) | CYP19A1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-6077853-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | CYP19A1 368/4885S1PR1 2119/4885S1PR3 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.